[Biological and clinical features of alpha 1-antitrypsin with special reference to malignant processes. III].
D000510:Alpha-Globulins / Q000032:analysis; D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology; D002286:Carcinoma, Ehrlich Tumor / Q000201:enzymology; D006528:Carcinoma, Hepatocellular / Q000201:enzymology; D004386:Duodenum; D005260:Female; D005750:Gastric Juice / Q000201:enzymology; D005767:Gastrointestinal Diseases / Q000201:enzymology; D006801:Humans; D007419:Intestinal Secretions / Q000201:enzymology; D008107:Liver Diseases / Q000201:enzymology; D008113:Liver Neoplasms / Q000201:enzymology; D008171:Lung Diseases / Q000201:enzymology; D008297:Male; D051379:Mice; D009369:Neoplasms / Q000201:enzymology / Q000276:immunology; D012016:Reference Values; D014361:Trypsin Inhibitors / Q000097:blood; D000515:alpha 1-Antitrypsin / Q000032:analysis / Q000378:metabolism*; D000511:alpha-Macroglobulins / Q000032:analysis
D000510:Alpha-Globulins; D000912:Antibodies, Neoplasm; D014361:Trypsin Inhibitors; D000515:alpha 1-Antitrypsin; D000511:alpha-Macroglobulins
Aspectos biológicos y clínicos de la alfa-1-antitripsina, con especial referencia a los procesos tumorales malignos. Parte III.